PE-22-28: 100 published COA source records
1 study on PE-22-28 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 100 published PE-22-28 COA source records from third-party laboratories, covering 54 publicly attributable vendor identities. Across 92 records with positive numeric purity, the arithmetic mean is 99.63%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 5 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-06. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
PE-22-28 average prices
As of 2026-09-13, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $10.17 | $9.50–$10.50 | $1.02 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
PE-22-28: published third-party laboratory evidence
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-06. Aggregate calculated: 2026-09-13T23:32:53.869477+00:00. Calculation time is not a laboratory observation date.
Within that total, 23 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Top 3 vendor evidence profiles for PE-22-28
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.76% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 4 | 99.54% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 3 | 99.79% | 0 of 3 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #104593 (99.74%) · #103912 (99.74%) · #104914 (99.31%) · #103241 (99.33%) · #103918 (99.59%) · #101406 (99.72%)
PE-22-28 studies and clinical research
-
Unique Protein Helix Powers Key Cellular Recycling Enzyme ATG3
This research provides fundamental insights into the mechanisms governing autophagy, a process vital for cellular health and implicated in numerous diseases, including cancer, neurodegeneration, and infectious disease…
Research tools
Free, no account — handy when you're working with PE-22-28.
